Pharmacokinetics, bioavailability and serum levels of cardiac glycosides
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Digoxin, the cardiac glycoside most frequently used in clinical practice in the United States, can be given orally or intravenously and has an excretory half-life of 36 to 48 hours in patients with serum creatinine and blood urea nitrogen values in the normal range. Since the drug is excreted predominantly by the kidney, the half-life is prolonged progressively with diminishing renal function, reaching about 5 days on average in patients who are essentially anephric. Serum protein binding of digoxin is only about 20%, and differs markedly in this regard from that of digitoxin, which is 97% bound by serum albumin at usual therapeutic levels. Digitoxin is nearly completely absorbed from the normal gastrointestinal tract and has a half-life averaging 5 to 6 days in patients receiving usual doses irrespective of renal function. The bioavailability of digoxin is appreciably less than that of digitoxin, averaging about two-thirds to three-fourths of the equivalent dose given intravenously in the case of currently available tablet formulations. Recent studies have shown that gut flora of about 10% of patients reduce digoxin to a less bioactive dihydro derivative. This process is sensitive to antibiotic administration, creating the potential for important interactions among drugs. Serum or plasma concentrations of digitalis glycosides can be measured by radioimmunoassay methods that are now widely available, but knowledge of serum levels does not substitute for a sound working knowledge of the clinical pharmacology of the preparation used and careful patient follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the allometric exponent for VD commonly approximates 1.0, certain highly lipophilic or tissue-binding drugs, such as amiodarone [33] and digoxin [34], exhibit volumes that are substantially higher than predicted.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [34]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacological Basis of Therapeutics
Leopold, I. H. (1971) · American Journal of Ophthalmology · doi:10.1016/0002-9394(71)91343-2 · Cited by 1,668
Determination of Therapeutic and Toxic Serum Digoxin Concentrations by Radioimmunoassay
Smith, T. W., Butler, V. P., & Haber, E. (1969) · New England Journal of Medicine · doi:10.1056/nejm196911272812203 · Cited by 583
Self-citationDigitalis Intoxication: A Prospective Clinical Study with Serum Level Correlations
Beller, G. A., Smith, T. W., Abelmann, W. H., Haber, E., & Hood, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197105062841801 · Cited by 571
Self-citationInactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Clinical Pharmacokinetics of Digoxin
Iisalo, E. (1977) · Clinical Pharmacokinetics · doi:10.2165/00003088-197702010-00001 · Cited by 265
Plasma Digoxin Concentrations in Patients with Atrial Fibrillation
Chamberlain, D. A., White, R. J., Howard, M. R., & Smith, T. W. (1970) · BMJ · doi:10.1136/bmj.3.5720.429 · Cited by 208
Self-citationPart I Digitalis glycosides: Mechanisms and manifestations of toxicity
Smith, T. W., Antman, E. M., Friedman, P. L., Blatt, C. M., & Marsh, J. D. (1984) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(84)90012-4 · Cited by 197
Self-citationALTERED ABSORPTION OF DIGOXIN IN PATIENTS GIVEN PROPANTHELINE AND METOCLOPRAMIDE
Manninen, V., Melin, J., Apajalahti, A., & Karesoja, M. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90252-3 · Cited by 196
Renal Tubular Secretion of Digoxin
STEINESS, E. (1974) · Circulation · doi:10.1161/01.cir.50.1.103 · Cited by 184
Janowitz, H. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91317-3 · Cited by 178
Research works printed but not linked: 1
- Lindenbaum, 1970, Impairment of digoxin absorption by neomycin (abstr), Clin Res, 20, 410
Cited by
Digitalis: Mechanisms of Action and Clinical Use
Epstein, F. H., & Smith, T. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802113180606 · Cited by 346
Self-citationBotelho, A. F. M., Pierezan, F., Soto-Blanco, B., & Melo, M. M. (2019) · Toxicon · doi:10.1016/j.toxicon.2018.11.429 · Cited by 184
Role of P-Glycoprotein Inhibition for Drug Interactions
Eberl, S., Renner, B., Neubert, A. C., Reisig, M., Bachmakov, I., König, J., Dörje, F., Mürdter, T. E., Ackermann, A., Dormann, H., et al. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746120-00004 · Cited by 120
Schlehuber, S., Beste, G., & Skerra, A. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3646 · Cited by 115
Hanks, G. E., Hanlon, A., Pinover, W. H., Horwitz, E. M., & Schultheiss, T. E. (1999) · PubMed · Cited by 110
Metadata
- Authors
- Smith, T. W.
- Corresponding author
- Smith, Thomas W.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 1985-05
- Volume
- 5
- Issue
- 5
- Pages
- 43A-50A
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2069114074
- Cited by
- 69
- References
- 53
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 2 · 2023: 6 · 2022: 1 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 1 · 2014: 3 · 2012: 1
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 10303 d)
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- digoxin, digitoxin, cardiac glycosides, pharmacokinetics, bioavailability, plasma protein binding, renal excretion, half-life, drug interactions, radioimmunoassay, serum concentration monitoring
- MeSH terms
- Absorption, Biological Availability, Cardiac Glycosides, Cost-Benefit Analysis, Digitoxin, Digoxin, Half-Life, Humans, Kinetics, Radioimmunoassay, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. https://app.cochat.ai/papers/10.1016/s0735-1097(85)80462-9
- The paper
- Smith, T. W. (1985). Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. Journal of the American College of Cardiology. https://doi.org/10.1016/s0735-1097(85)80462-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.